NCT05593692 Gender Differences and Age Related Differences in Emergency Department Admission
| NCT ID | NCT05593692 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Emergencies |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2022-10-18 |
| Primary Completion | 2025-07-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2022-10-18 with a primary completion date of 2025-07-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about difference related to age and gender in patients admitted to emergency department.
Eligibility Criteria
Inclusion Criteria: * Age over 18 y * Admitted to emergency department Exclusion Criteria: * Age under 18 y
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05593692 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Emergencies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05593692 currently recruiting?
Yes, NCT05593692 is actively recruiting participants. Contact the research team at marcello.covino@policlinicogemelli.it for enrollment information.
Where is the NCT05593692 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT05593692 clinical trial?
NCT05593692 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 15,000 participants.